T. Zahaf

发表

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Daron G Ferris, Diane M Harper, Gary Dubin, 2004, The Lancet.

Computation of the exact information matrix of Gaussian dynamic regression time series models

G. Mélard, A. Klein, T. Zahaf, 1998 .

Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women.

C. Wheeler, A. Moscicki, D. Ferris, 2012, Vaccine.

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Shinn-Jang Hwang, M. Levin, T. Vesikari, 2015, The New England journal of medicine.

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials

Debora A. Rausch, M. Levin, C. Hervé, 2020, Rheumatology.

Nonparametric tests of independence of two autoregressive time series based on autoregression rank scores

M. Hallin, J. Jurecková, J. Picek, 1999 .

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su)

T. Heineman, T. Zahaf, Himal Lal, 2013, Human vaccines & immunotherapeutics.

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

H. Ikematsu, Shinn-Jang Hwang, T. Mrkvan, 2019, Human vaccines & immunotherapeutics.

Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

Shinn-Jang Hwang, L. Cámpora, E. Ledent, 2019, Vaccine.

Non‐parametric tests in AR models with applications to climatic data

M. Hallin, J. Picek, J. Kalvová, 1997 .

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Lidia Oostvogels, Jan Smetana, Daisuke Watanabe, 2016, The New England journal of medicine.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

B Romanowski, H. Kitchener, M. Lehtinen, 2009, The Lancet.

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

P. Naud, B. Geeraerts, J. Teixeira, 2014, Human vaccines & immunotherapeutics.

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

C. Wheeler, H. Kitchener, M. Lehtinen, 2015, Clinical and Vaccine Immunology.

Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

M. Einstein, M. Levin, G. Dubin, 2010, Human vaccines.

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.

P. Naud, N. S. Carvalho, J. Teixeira, 2010, Vaccine.

ustained efficacy and immunogenicity of the HPV-16 / 18 AS 04-adjuvanted accine up to 7 . 3 years in young adult women

T. Zahaf, J. Teixeirab, D. Carvalhoa, 2010 .

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

C. Wheeler, D. Harper, A. Moscicki, 2009, The Lancet.

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

A. Schneider, G. Dubin, T. Schwarz, 2009, Vaccine.

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.

Thomas Breuer, Marie-Pierre David, Gary Dubin, 2008, Vaccine.

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, International journal of cancer.

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

P. Naud, B. Geeraerts, J. Teixeira, 2012, Human vaccines & immunotherapeutics.

Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial

Daron G Ferris, Wim Quint, Diane M Harper, 2005 .

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine

C. Wheeler, D. Harper, W. Quint, 2007 .

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.

A. Cunningham, V. Wascotte, A. Schuind, 2019, Vaccine.

Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies

A. Callegaro, Naveen Karkada, T. Zahaf, 2023, Pharmaceutical statistics.

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

M. Levin, A. Cunningham, C. Hervé, 2020, Human vaccines & immunotherapeutics.

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine

A. Callegaro, M. Levin, A. Cunningham, 2021, The Journal of infectious diseases.

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naïve population

C. Wheeler, H. Kitchener, M. Lehtinen, 2009 .

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial

C. Wheeler, D. Harper, W. Quint, 2005 .

H. Kitchener, M. Lehtinen, X. Castellsagué, 2012, The Lancet. Oncology.

H. Kitchener, M. Lehtinen, S. Garland, 2015, Clinical and Vaccine Immunology.